MARKET

TERN

TERN

Terns Pharmaceuticals, Inc.
NASDAQ
5.71
+0.11
+1.96%
After Hours: 5.71 0 0.00% 16:20 11/21 EST
OPEN
5.56
PREV CLOSE
5.60
HIGH
5.79
LOW
5.46
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
11.40
52 WEEK LOW
3.590
MARKET CAP
485.00M
P/E (TTM)
-4.8451
1D
5D
1M
3M
1Y
5Y
1D
Top 3 Health Care Stocks You'll Regret Missing In Q4
Benzinga · 2d ago
Terns Pharmaceuticals Appoints Heather Turner to Board of Directors, Ann E. Taylor Steps Down
Barchart · 3d ago
TERNS PHARMACEUTICALS APPOINTS HEATHER TURNER, J.D., TO BOARD OF DIRECTORS
Reuters · 3d ago
Press Release: Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Dow Jones · 3d ago
Weekly Report: what happened at TERN last week (1111-1115)?
Weekly Report · 3d ago
Insiders Re-Evaluate Their US$5.05m Stock Purchase As Terns Pharmaceuticals Falls To US$556m
Simply Wall St · 5d ago
Terns Pharmaceuticals Reports Q3 Progress and Financials
TipRanks · 11/14 04:34
Promising Phase 1/2 Study and Strong Financials Drive Buy Rating for Terns Pharmaceuticals
TipRanks · 11/14 00:25
More
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Webull offers Terns Pharmaceuticals Inc stock information, including NASDAQ: TERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TERN stock methods without spending real money on the virtual paper trading platform.